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Recently, it was shown that a  human red cell  (RBC) z membrane  glycoprotein of 
200,000 mol wt is a powerful inhibitor of one of the central enzymes of the complement 
system, the C3-convertase of the alternative pathway (1). This protein, identified as 
the immune-adherence receptor for the complement  fragments C3b and C4b  (CR1), 
(2)  was later shown to inhibit the classical pathway C3- and C5-convertases  (3). 
In human peripheral blood, CRz is found on erythrocytes, lymphocytes, neutrophils, 
and monocytes (4, 5). Although normal human RBC bear <2 ×  10 a molecules of CRz 
(2, 6), their presence can be detected by the immune-adherence  assay based on the 
agglutination of erythroeytes by C3b  (7, 8)  or C4b-bearing  (9)  immune complexes. 
Miyakawa et al. found that RBC from most patients with systemic lupus erythema- 
tosus  (SLE)  failed to exhibit immune-adherence and suggested  that the erythrocyte 
defect, presumably involving CRz, might be inherited rather than acquired  (10). 
To study this phenomenon further, we developed an immunoradiometric assay for 
human CR1,  using monoclonal antibodies,  and measured  its concentration in RBC 
from normal individuals and from patients with SLE and other diseases. 
Materials and Methods 
Monoclonal Antibodies.  Monoclonal antibodies against human CRI  were  produced  as  de- 
scribed by Kohler and Millstein (11). CRz was purifed to homogeneity from human erythro- 
cytes  (1), and 6/~g was incorporated into Freund's complete adjuvant and injected into mice. 
3 wk later, the mice were boosted with 6/~g of CR1  intraperitoneally, and the spleens were 
removed 3 d later and used for fusion with the mouse plasmacytoma cell line SP2 (12). 
The assay  for  the detection of antibody to CR1  secreted  by the hybrids into the culture 
medium was  performed as  follows. The wells of plastic plates (Dynatech Laboratories, Inc., 
Alexandria, VA) were coated with C3b by incubation with 50 #1 of purified C3b (13), 50 #g/ml 
in 0.02 M phosphate buffer, pH 7.6, at room temperature for 2 h. The wells were washed three 
times with  I%  bovine serum albumin (BSA)  in phosphate-buffered saline (PBS),  pH  7.4, 
containing  0.02% sodium azide (BSAopBS). Then 25 #1 of partially purified CR1 was added to 
the  wells  at  a  concentration that  saturated  the  CRa  binding sites  of the  solid-phase C3b. 
Partially purified CR1 was obtained as described by Fearon (1), except that the steps involving 
affinity chromatography on Sepharose  C3b and Sepharose-lentil lectin were omitted. After 
incubation for 1 h at room temperature, the wells were washed three times with 0.05% Tween 
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20 (Fisher Scientific Co., Pittsburgh, PA) in BSA-PBS. Then 25/zl of the culture supernatants 
was added to the individual wells. After incubation for 2 h at 4°C, followed  by three washes 
with  Tween-BSA-PBS,  25  /~1  (1  ng)  of  125I-radiolabeled  affinity-purified goat  anti-mouse 
immunoglobulin  (Ig) (5 X 107 cpm/#g) was added to each well. The antibodies were radiola- 
beled using Enzymobeads (Bio-Rad Laboratories, Richmond, CA), as described by the manu- 
facturer. After an additional incubation of the plates for  1 h at room temperature, the wells 
were  washed  four times with Tween-BSA-PBS, cut  individually, and counted in a  gamma 
counter.  The  cells  yielding positive supernatants were  cloned by  limiting dilution in  the 
presence of mouse thymocytes; the clones were expanded and then injected intraperitoneally 
into Pristane (Aldrich Chemical Co., Milwaukee, WI)-treated mice to obtain ascites fluid. 
Ig were  purified to homogeneity by ammonium sulfate precipitation, followed  by column 
chromatography on DEAE Sephacel and Sephadex G-200 (Pharmacia Fine Chemicals, Div. of 
Pharmacia Inc., Piscataway, N  J). Both monoclonal antibodies used in this study, 57F and 44D, 
were typed as IgGI,K. A monoclonal antibody (3D11) against a malaria antigen was also typed 
as IgG1,K and was used in control experiments (14). 
Preparation of Cells.  Lymphocytes were obtained by centrifugation of suspensions of tonsil 
cells on Ficoll-Paque (Pharmacia Fine Chemicals) cushions (15). Cells were obtained from fresh, 
citrated  peripheral blood of normal individuals and patients.  Mononuclear cells  were  first 
separated  by  Ficoll-Paque. A  population of lymphoid cells  enriched  for  T  cells  was  then 
obtained by passage  of the mononuclear cells through a nylon wool column (16), followed  by 
repeated panning on petri dishes coated with affinity-purified  F(ab')2 fragments of rabbit anti- 
human IgG (17). The final preparation contained 2.7% lymphocytes that formed rosettes  with 
EAC14°~Y23b. Polymorphonuclear cells (PMN) were separated by centrifugation on cushions 
of Percoll (Pharmacia Fine Chemicals) (18). Erythrocytes were washed four times with 0.15 M 
NaCI, carefully removing the buffy coat after each centrifugation. 
Blood  samples were  obtained from  34  SLE  patients from  Bellevue Hospital-New York 
University Medical Center, and The Rockefeller University, New York. All patients fulfilled at 
least  four of the preliminary criteria for the diagnosis of SLE (19). There were 5 males and 29 
females,  ranging in age from 19-55 yr old (mean, 34 yr). The duration of the illness was from 
4  mo to  15 yr (mean, 8 yr). At the time of the study, 20  patients were  being treated with 
prednisone, with daily doses ranging from 5-100 mg.  13 of these  patients had active disease. 
Blood samples were also obtained from 7 asthmatics, males and females,  who were receiving 
daily doses of >40 mg of prednisone or equivalent, and from  10 patients with sero-positive 
rheumatoid arthritis. The controls consisted of 52 healthy male and female blood donors and 
laboratory personnel, ranging in age from 20 to 55 yr old. 
Immunoradiometric Assay for CR1 in Cell Extracts.  The cell extracts were prepared as follows: 4 
×  109 packed, washed erythrocytes were lysed with 200 #1 of 1% Nonidet P-40 (NP-40, Particle 
Data Inc., Elmhurst, IL) in PBS containing 50 p.g/ml of the synthetic elastase inhibitor Suc 
(OMe)-Ala-AIa-Pro-VaI-MCA (Peninsula Laboratories,  Inc.,  San  Carlos,  CA)  and  1 mM 
phenylmethylsulfonyl fluoride (PMSF). After 1 h of incubation with occasional agitation by 
vortexing, the  volume was  brought  to  2  ml  with  BSA-PBS  containing the  same  protease 
inhibitors and centrifuged at 50,000 g for 30 min. 
In the case of other cell populations, an identical procedure was used, except that the lysing 
buffer also  contained 200  U/ml of deoxyribonuclease I  (Worthington Biochemical Corp., 
Freehold, N  J). The final concentration of neutrophils or mononuclear cells in the extracts was 
2 ×  10V/ml, and the concentration of T cells in the extracts was 10a/ml. 
The immunoassay was performed as follows: 25 #1 of two dilutions of the cell extracts in 
BSA-PBS containing 0.1% NP-40 were added to C3b-coated plastic wells that were  prepared 
as described in the assay for the detection of monoclonal antibodies. After 2 h of incubation at 
37°C,  the  wells  were  washed  three  times with Tween-BSA-PBS. Then 25 /tl  of a  2 #g/ml 
solution of  125I-labeled monoclonal antibody to  CR1  (57F)  was  added  to  the  wells.  The 
monoclonal antibody was also radiolabeled using Enzymobeads. After an additional incubation 
for  1 h  at  room  temperature, the wells  were  washed  four times with Tween-BSA-PBS, cut 
individually, and counted in a  gamma counter. The amounts of CR1  in the extracts  were 
calculated from a  standard curve obtained with purified CRI, which was  included in each 
series of determinations (Fig.  1). KYOKO  IIDA,  RICARDO MORNAGHI, AND VICTOR  NUSSENZWEIG  1429 
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FIG.  1. 
assay. 
Standard curve obtained by titrating purified CR1 by means of the immunoradiometric 
Immunoassayfor Measuring CR1 on Cell Surfaces.  107 erythrocytes were incubated with  100  ng 
of 125I-labeled  monoclonal (57F)  in 200/~1  of BSA-PBS at  37°G. After incubation for 30 rain, 
triplicate samples of 50/d of the reaction mixtures was layered onto 300 #1 of a mixture of 8 vol 
of dibutyl  phthalate  (Fisher)  and  2 vol of dinonylphthalate  (Eastman  Kodak Go., Rochester, 
NY) in Beckman microtest tubes  (Beckman Instruments  Inc., Fullerton, CA). The tubes were 
centrifuged at 8,000 g  for 90 s in a  Beckman B  microcentrifuge (Beckman Instruments,  Inc.). 
The tips of the tubes were cut and counted in a  gamma counter. 
Rosette Formation between CRl-bearing  Cells and  Sheep ETythrocytes Sensitized  with  Antibody and 
Complement.  To prepare EAG14°xY23b,  sheep erythroeytes (E) were sensitized with rabbit IgM 
antibodies (A) to sheep E  (Cordis Laboratories Inc., Miami, FL) and reacted sequentially with 
complement (C) components, guinea pig C1  (20), human G4 (21), and °xuC2 (22) at concentra- 
tions  calculated  to  form  300  hemolytic sites  per cell.  To this  cellular intermediate,  limiting 
amounts of human C3 (23) were added to generate about two hemolytic C3 sites per cell. These 
cells (EAC14°xY23b)  were suspended  at  1 ×  10  s cells/ml in RPMI  1640  (Gibco Laboratories, 
Grand Island Biologic Co., Grand Island, NY) with  1% Hepes buffer and 0.1% sodium azide, 
pH  7.4.  To form rosettes,  300 #1 of this suspension  was mixed with  150/~1 of the same buffer 
and  150/~1 of lymphocytes (4 ×  106) and was incubated,  rotating continuously, for 30 min at 
37°C.  300 lymphocytes were counted under  the microscope and scored for rosette formation. 
Controls  incubated  with  EAC14°'Y2  did  not  form  rosettes.  To  determine  the  effect  of the 
monoclonals 57F and  44D on rosette formation, the lymphocytes were preincubated  at 37°C 
for 30 min with 150/~1 of various antibody dilutions and then mixed with 300 #l of EAG14°xY23b 
for rosette formation. 
Surface Labeling of Lymphocytes and Immunoprecipitation of Membrane Proteins.  3  ×  l0  T tonsil 
lymphocytes, purified as above and suspended  in  1 ml PBS, were radiolabeled with  1 mCi of 
125  Na  I in a  glass tube coated with Iodogen (Pierce Chemical Co., Rockford, IL). After 10 rain 
at  room  temperature,  the  reaction  mixture  was  layered  on  1  ml  of fetal  calf serum  and 
centrifuged. The pelleted cells were further washed twice with PBS. Cells were lysed with 200 
/~1 of 1% NP-40 in PBS containing 50 #g/ml of the elastase inhibitor Suc(OMe)-Ala-AIa-Pro- 
VaI-MCA, 200 U/ml of DNase, and  1 mM PMSF. After 1 h at room temperature, the extracts 
were centrifuged at  12,000 g for 10 rain. 
20/~1  of the supernatant  was immunoprecipitated  with 20 #1  (20/~g)  of various antibodies 
and  control  proteins:  monoclonals  57F,  44D,  polyclonal  anti-GR1  rabbit  IgG,  and  mouse 1430  SYSTEMIC LUPUS ERYTHEMATOSUS COMPLEMENT  RECEPTOR  DEFICIENCY 
myeloma protein MOPC  21  (Meloy Laboratories, Inc., Springfield, VA).  After incubation 
overnight at 4°C,  100 ~1 of a  10% suspension of Staphylococcus aureus (Staph A, Calbiochem- 
Behring Corp., American Hoechst Corp., San Diego, CA) was added and the mixture further 
incubated at 0°C for 30 min. The Staph A was collected by centrifugation and washed four 
times with PBS containing  0.1% NP-40 and 0.05% deoxycholate. The proteins bound to Staph 
A were eluted with 50 #1 Tris, pH 6.8, containing 2% sodium dodecyl sulfate (SDS), 6 M urea, 
and 20% 2-mercaptoethanol. 
The eluted materials were  subjected to  SDS  polyacrylamide gel  electrophoresis  (PAGE) 
according to the method of Laemmli (24). 4.5% running and 3% stacking gels were used, and 
radioautography was  carried  out  by exposing the  dried  gel  to  an X-Omat  R  film  (XR-5, 
Eastman Kodak Co.) at -70°C. 
Titration of C4 Hemolytic Activity and Circulating Immune Complexes.  C4 hemolytic activity was 
titrated using cellular intermediates prepared with guinea pig complement components. Clq- 
binding assays (25) and Raji cell assays (26) for the detection of immune complexes were kindly 
performed by Dr. A. Theophilopoulos (Scripps Clinic, La Jolla, CA). The above determinations 
were performed in plasma and sera from SLE patients with active and inactive disease. 
Results 
Characterization  of  the  Monoclonal  Antibodies  57t7  and  44D.  By  two  criteria,  the 
monoclonal antibodies 57F and 44D are directed against CR1. They immunoprecip- 
itated a single polypeptide of molecular weight identical to that of purified CRI, from 
extracts of surface-labeled tonsil lymphocytes (Fig. 2), and at very low concentrations 
they inhibited rosette formation between RBC bearing C3b and lymphocytes (Table 
I). 
Ft~. 2.  Immunoprecipitation of CRa from the cell surface by monoclonal antibodies. The surlb.ce 
membranes of tonsil lymphocytes  were radiolabeled, and the extracts were immunoprecipitated by 
various antibodies. The immunoprecipitated materials were analyzed by SDS-PAGE and radioau- 
tography. The position of purified CRx, which was electrophoresed and stained in the same gel, is 
shown by the arrow. As seen, both the monoclonal antibodies 57F and 44D as well as a polyclonal 
rabbit anti-CRl (l) immunoprecipitated CRI. KYOKO  IIDA,  RICARDO  MORNAGHI,  AND  VICTOR  NUSSENZWEIG 
TABLE  I 
Inhibition of Rosette Formation between EA C14°~Y  23b and Tonsil 
Lymphocytes by Monoclonal Antibodies 
Inhibition of rosette  Monoclonal antibodies  Concentration  formation* 
ng/ml  % 
44D  2,000  86 
200  89 
20  85 
2  87 
0.2  50 
57F  20,000  79 
2,000  50 
2OO  39 
2O  55 
0.2  0 
3D11  20,000  0 
(Control)  200  0 
* 24% of cells in this preparation formed rosettes with EAC14  °xy 23b in the 
absence of antibodies; no rosette formation occurred with EAC 14  °Xy 2. 
TABLr  II 
Distribution of CR1 among Cell Populations* 
Ceils  Treatment  CR1 mole- 
cules/cell 
Tonsil  Mononuclear  None  1.8 ×  10  2 
Trypsin~  0 
Peripheral blood  Erythrocytes  None  1.4 ×  10  a 
Trypsin~:  0 
Mononuclear, total  None  3.8 ×  10  4 
PMN  None  1.4 ×  10  5 
T lymphocytes§  None  7.0 X  10  2 
Raji  None  0 
* The concentrations of CRI  were measured in cell extracts, as described in 
Materials and Methods. 
Cells were incubated with trypsin, 100/Lg/ml for 30 min at 37°C, and the 
reaction was stopped by adding soybean trypsin inhibitor. 
§This  population  contained  2.7%  of  cells  that  formed  rosettes  with 
EAC 14°xY23b. 
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The  monoclonals  were also used to measure  the concentration  of CRx  in cells from 
human  peripheral  blood and  tonsils and  in Raji cells (27). As shown  in Table  II, CRa 
was not detectable on Raji cells. Mononuclear  cells from tonsils and peripheral  blood 
had  1.8 ×  105 and 3.8 ×  104 CRa molecules per cell, respectively. By rosette formation 
with  EAC14°xY23b,  the  tonsils contained  ~50%  B  lymphocytes.  Assuming  that  the 
other cells do  not contain  CR1,  we calculate that  the B  lymphocytes  have  3.6  ×  105 
CRI  molecules.  By  the  same  reasoning,  the  CRl-positive  cells of human  peripheral 
blood  (monocytes  and  B  lymphocytes),  which  constitute  ~15%  of the total mononu- 
clear cells, bear an average of 2.5 ×  105 CR1 molecules. The  number  of CR1 molecules 
in neutrophils  and erythrocytes was  1.4 ×  105 and  1.4 ×  103, respectively.  Extracts of 1432  SYSTEMIC  LUPUS  ERYTHEMATOSUS  COMPLEMENT  RECEPTOR  DEFICIENCY 
purified  T  lymphocytes contained  small  numbers  of CR1  molecules  (7  ×  10Z/cell), 
which could be accounted for entirely by the presence in this population of 2.7% of 
cells  that  formed  rosettes  with  EAC14°xY23b  and  which  could  be  contaminating 
monocytes or B lymphocytes. 
An additional point of interest was that, when tonsil cells were treated with trypsin 
(100  #g/ml,  30  min,  at  37°C),  CRa  could  no  longer  be  detected  in  the  extracts, 
implying that most CR1 molecules of B lymphocytes were surface bound. 
Although both monoclonals recognized CR1 and inhibited its function, they bound 
to separate epitopes of the molecule. This was determined by measuring the binding 
of the ~2SI-labeled  monoclonals to plastic plates coated with CRy, as described in the 
legend of Fig. 3. Under saturating conditions, the specific counts bound to CRy, using 
a  mixture of 57F and 44D, were equal to the sum of the counts obtained with each 
monoclonal separately. Furthermore, the amounts of labeled 44D that bound to the 
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F]~.  3.  The monoclonal antibodies 57F and 44D bind to separate epitopes ofCR]. CR] was bound 
to  C3b-coated  plates,  as  described  in  Materials  and  Methods.  The  radiolabeled  monoclonal 
antibodies, either separately or as a mixture, were added. After 1 h of incubation, wells were washed, 
cut  individually,  and counted. The numbers in the abscissa represent the  final concentrations of 
each monoclonal antibody in wells. The results show that under saturating conditions the number 
of counts bound to the wells that received  a mixture of 57F plus 44D represent approximately the 
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FIG. 4.  Number of CR1 molecules on erythrocytes from normal individuals and patients. CR] were 
measured in extracts of RBC from 52 normal individuals, 34 SLE, 10 RA, and 7 asthmatic patients, 
using an immunoradiometric assay. The CR1 levels of the SLE patients are significantly diminished. KYOKO  IIDA,  RICARDO  MORNAGHI,  AND  VICTOR  NUSSENZWEIG  1433 
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FIG.  5.  Correlation between CRI measurements in RBC extracts using two monoclonal antibodies. 
CRI titrations in extracts of RBC from normal individuals (O) and SLE patients (/k) were performed 
by immunoradiometric assay. Two assays were performed in each sample, using either antibody 
57F or 44D. The correlation coefficient between the two measurements was 0.96 (P <  0.001). 
CRa-coated plates were not influenced by the presence of high concentrations of cold 
57F and vice versa (data not shown). 
CRx Levels in Normal Individuals and Patients.  CR1 was measured in extracts of RBC 
of 52  healthy  volunteers  using  monoclonal  57F  (Fig.  4),  and  the  number  of CRx 
molecules per cell was  estimated  as  1,410  +  620.  No  significant  differences in  the 
receptor levels were observed when the individuals were grouped by sex, blood group, 
(A, B, O), or age (20-29, 30-39, and 40-55 yr of age). 
As shown in Fig.  5, we also measured CR1 in the extracts, using monoclonal 44D 
instead of 57F. The correlation coefficient between the results of the two measurements 
was 0.96  (P <  0.001).  A separate immunoassay was used to estimate the amounts of 
CRx on cell surfaces  (see  Materials and Methods).  When  the results were compared 
with the CRa concentrations in the corresponding extracts, the correlation coefficient 
was 0.98  (P <  0.001). 
In 34 SLE patients,  the CRa levels in  RBC extracts  (600  _  307  molecules/RBC) 
were significantly lower than  those of normals  (P <  0.001).  To determine whether 
CR1 varies in the course of disease, we performed sequential determinations in some 
patients.  Four individuals were tested during disease activity and in remission. Two 
patients showed large increases (80% and 176%) of CR1 levels when in remission, and 
in the others, the low CRI value did not change. 
In 10 patients with rheumatoid arthritis, the CR1 levels were 903 ±  417 molecules/ 
RBC, a value that is also significantly below normal (P <  0.02). To verify whether the 
administration of steroids lowers the levels of CRa on erythrocytes, we studied seven 
asthmatics undergoing long-term treatment with  prednisone or an equivalent  drug. 1434  SYSTEMIC  LUPUS ERYTHEMATOSUS  COMPLEMENT  RECEPTOR  DEFICIENCY 
The CR1 values in this group (1,560 +  500 molecules/RBC) did not differ significantly 
from those of normal individuals. 
Correlation between C4 Levels, Circulating Immune Complexes, and CR1  Values in Patients 
with SLE.  C4 hemolytic titrations were performed in plasmas from 24 patients with 
SLE and in  18 age- and sex-matched normal volunteers. The C4 levels in the patients 
and  controls  were  29,500  units  __.  20,400  and  39,000  ___  15,400,  respectively.  The 
correlation coefficient between CR1 and C4 levels was 0.56 (P <  0.01)  in patients and 
0.038  (P I> 1)  in normal individuals. 
Raji  cells  and  solid-phase Clq-binding  assays  for circulating  immune complexes 
were performed in 20 serum samples from SLE patients. The mean values were 955 
___  756  (normal values, <17)  for the Raji  cell assay and  181  ___  122  (normal  values, 
< 13) for the Clq-binding assay expressed in/~g of aggregated human gamma globulin 
equivalents. When  these values were compared to CR~ levels in the same patient, a 
negative correlation was found with the results of the Clq-binding assays (r =  -0.49, 
P <  0.05)  but not with the Raji assay (r -- 0.32, P >  0.2). 
Discussion 
The present study reports quantitative information on the distribution of comple- 
ment  receptor  (CR1)  molecules  in  normal  individuals  and  in  patients.  The  CR1 
measurements were made using monoclonal antibodies. The antibody specificity was 
confirmed by immunoprecipitation of CR1 from extracts of surface-labeled cells, by 
inhibition  of rosette formation between  B  lymphocytes and  the  RBC  intermediate 
EAC14°xY23b,  and  by the  characteristic  distribution  of the  antigen  among cells  of 
human peripheral blood. 
According  to  these  measurements,  we  estimate  that  B  lymphocytes bear  the 
highest  number  of CR1  molecules  (3.6  ×  105) on  their  membranes,  followed  by 
neutrophils  (1.4  X  10  ~)  and RBC  (1.4  ×  10a), whereas T  lymphocytes are negative. 
However, as pointed out by Siegel et al. (28) and Medof and Oger (29), if the ratio of 
RBC  to leukocytes is taken  into consideration,  >90%  of CR1  in  human  peripheral 
blood  is  erythrocyte  associated.  Therefore,  in  theory,  complement-fixing  immune 
complexes formed in circulation  might first encounter CRa of RBC.  Indeed,  Medof 
and Oger (29) have added immune complexes prepared with labeled antigen to whole 
human  blood  and  found  that  in  <5  min,  80-85%  of  the  counts  became  RBC 
associated.  These  experimental  findings  and  the  observations  of Nelson  (30),  that 
RBC  seem  to  be involved  in  the  clearance  of complexes  from circulation,  might 
provide  an  explanation  for  the  decrease  in  the  number  of CR1  observed  in  SLE 
patients (see below). 
The number of CR1 in extracts of RBC from 52 normal individuals 20-55 yr of age 
varied from 250-3,000 molecules per erythrocyte. Because of the wide range of values 
obtained,  we  performed  several  experiments  to  exclude  some  possible  sources  of 
systematic  error.  For  example,  the  assay  for  CRa  in  RBC  extracts  involved  two 
successive specific steps, i.e., the binding of the receptor to solid-phase C3b, followed 
by the  titration  of the  bound  receptor  using  a  radiolabeled  monoclonal  antibody 
(57F). It could be argued that the wide differences in CR1 levels in RBC from normals 
is artefactual and a  reflection of the presence in the population  tested of structural 
variants (allotypes) of CR1 with different affinities for C3b and/or for the monoclonal 
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To  study  the  influence  of the  monoclonals,  we  repeated  the  titrations  in  RBC 
extracts using monoclonal 44D  instead  of 57F.  In other experiments, we measured 
CR1 on the membrane of intact cells, using an assay that is independent of the affinity 
of the receptor for C3b. The correlation between  the results of these measurements 
performed simultaneously in samples of RBC from the same individuals was highly 
significant.  Because  the  two  monoclonals  are  directed  against  separate epitopes  of 
CR1, it is unlikely that the large variation in CR1 values is caused by the presence of 
structural variants of CR1 in the population studied. 
We  also  found  that  the  CR1  levels  of RBC  in  several  normal  volunteers  were 
remarkably  stable.  In  four  individuals,  two  of whom  had  low  CR1  levels  (<300 
molecules per cell), we performed a series of determinations during a period of 6 mo. 
In every case, the values of CR1 varied <10% around the mean (results not shown). 
Of some interest is the finding that the Raji cell line does not have detectable CR1. 
Raji cells have been used to measure circulating immune complexes (26)  in humans, 
and  the  nature  of their  membrane-associated  complement  receptor  has  been  the 
subject  of some controversy (31,  32).  In light of the present observations, Raji cells 
either  have a  membrane receptor  for C3b  different  from CR1  or,  more likely,  the 
receptor recognizes a  modified  form of C3b,  perhaps resulting  from its interaction 
with control proteins (32). 
We also measured CR~ levels on RBC from patients with autoimmune diseases. A 
low number of CR1  molecules was found on erythrocytes of individuals  with  SLE. 
This finding explains previously reported observation  (10,  33)  of defective immune- 
adherence properties of the patients' erythrocytes. The cause of the diminution in the 
expression  of CR1  is  unknown.  The  defect  is  not  uniquely  characteristic  of SLE 
patients  because  low  CR1  levels  were  also  observed  in  patients  with  rheumatoid 
arthritis.  It is  unlikely  that  corticosteroids  are responsible because CRa  levels were 
normal  in  extracts  of  RBC  from  asthmatic  individuals  receiving  high  doses  of 
prednisone. 
The defect could represent a secondary manifestation of the presence in circulation 
of immune complexes and/or  autoantibodies  to CR1.  The ligands  could  block the 
receptors,  mediate  the  removal of some of the  modified  RBC  from circulation,  or 
promote the internalization  of the receptors from the membrane of RBC precursors 
(34).  Some of our findings are compatible with this hypothesis. For example, signifi- 
cant  correlations  were  found  between  CR1  and  the  levels  of circulating  immune 
complexes as well as between CR~ and hemolytic titers of C4 in serum. Also, in two 
out of four patients with SLE, the levels of CR1 increased substantially after remission, 
showing that the deficiency is at least in part reversible. 
An alternative explanation, however, is that the defect is genetically controlled and 
that  individuals  with  low  CR1  levels  are  more  prone  to  develop  certain  immune 
complex diseases. In other words, the CR1 defect might precede disease and contribute 
to the accumulation of immune complexes in circulation. 
Whatever the mechanisms involved, it seems likely that they will also affect CR1 of 
other  cells.  Indeed,  Kazatchkine  et  al.  (35)  and  Emancipator  et  al.  2 have recently 
shown that CR1  antigen  is diminished or absent  in  glomeruli of SLE patients with 
proliferative glomerulonephritis. 
Emancipator, S.  N.,  K.  Iida, V.  Nussenzweig, and  G. Gallo. Monoclonal antibodies to  human 
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CR1 plays an important role in phagocytosis (4) and probably participates in events 
leading to the clearance of certain types of immune complexes from circulation  (36, 
37).  A  defect in CR1 might lead to alterations in the fate of immune complexes and 
of associated antigens. These abnormalities may be particularly severe in SLE patients 
whose Fc receptors presumably are functionally altered  (38), and may contribute to 
an enhanced deposition of immune complexes in tissues. 
Our findings imply that SLE should be added to the growing list of disorders whose 
pathophysiology involve defects in membrane receptors. Additional studies, however, 
are necessary to clarify the nature of the CR1 defect and its role in disease. It would 
also be of interest  to determine whether CR1  levels are a  good indicator of disease 
activity.  The  availability of sensitive  and  quantitative  assays  to  measure  the  CR1 
antigen  in  extracts  of cells  and  on  cell  surfaces  should  facilitate  the  experimental 
approach to these problems. 
Summary 
This study reports quantitative  information on the concentration  of complement 
receptor for C3b and C4b (CR1) on erythrocytes from normal individuals and patients 
with  immune complex disease.  The measurements were performed by an immuno- 
radiometric assay using monoclonal antibodies against CR1. The antibody specificity 
was confirmed by immunoprecipitation of CR1 from extracts of surface-labeled cells, 
by  inhibition  of rosette  formation  between  B  lymphocytes  and  the  erythrocytes 
intermediate  EAC14°xY23b,  and  by  the  characteristic  distribution  of  the  antigen 
among cells of human peripheral blood. 
The  number of CR1  molecules  in  erythrocytes  from  52  normal  individuals  was 
estimated as 1,410 _+ 620. No significant differences in CRa levels were observed when 
individuals  were  grouped  by sex,  age,  or blood  groups.  In  patients  with  SLE  and 
rheumatoid arthritis, the number of CR1 molecules per RBC was significantly lower, 
i.e.,  600  -  307  and  903  +  417,  respectively. CR1  levels were normal in  asthmatics 
undergoing long-term treatment with prednisone. In SLE patients, significant corre- 
lations were found between CRa levels, C4 hemolytic titers, and levels of circulating 
immune  complexes.  In  two  out  of four  patients  with  SLE,  CR1  levels  increased 
significantly  during  remission,  showing  that  the  deficiency  is,  at  least  in  part, 
reversible. The deficiency in CR1 could be genetically controlled or could represent 
an epiphenomenon caused by the interaction of the receptor with a ligand present in 
the circulation of patients. 
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